Valuation: Insmed Incorporated

Market Cap 26.73B 24.38B 22.54B 20.34B 38.31B 2,498B 39.83B 272B 108B 1,348B 100B 98.19B 4,258B P/E 2026 *
-75.5x
P/E 2027 * 174x
Enterprise Value 26.22B 23.91B 22.11B 19.95B 37.58B 2,450B 39.06B 267B 106B 1,322B 98.36B 96.3B 4,176B EV / Sales 2026 *
14.1x
EV / Sales 2027 * 8.62x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -
1 day-0.94%
Current month+7.26%
1 month+26.72%
3 months-6.00%
6 months+12.69%
Current year-30.62%
1 week 116.89
Extreme 116.8904
124.92
1 month 92.62
Extreme 92.625
124.92
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 11.31
Extreme 11.31
212.75
Manager TitleAgeSince
Chief Executive Officer 57 10/09/2012
Chief Tech/Sci/R&D Officer 62 19/12/2019
Chief Operating Officer 57 14/11/2019
Director TitleAgeSince
Chairman 75 16/06/2009
Chairman 57 08/11/2018
Director/Board Member 72 29/05/2014
Date Insider Type Main position Quantity % Market Cap. Importance
19/10/26 Free

Director

6,139 0.0028%
19/10/26 Free

Director

6,139 0.0028%
09/09/26 Sell

Director

-25,000 0.0114%
Change 5-day change 1-year change 3-year change Capi.($)
-0.95%0.00%-40.11%+390.45% 26.73B
-1.34%-4.12%+53.70%+68.83% 66.37B
+0.59%-1.83%+8.98%+90.68% 58.86B
+0.54%+0.45%+25.96%+86.62% 55.22B
-1.85%-3.45%+11.43%+115.83% 47.21B
+0.59%-5.60%+19.28%+26.25% 42.45B
-2.58%+2.22%+14.73%+41.28% 36.44B
-1.16%-11.20%+127.36%+638.47% 35.19B
-0.17%-1.83%+82.46%+57.48% 32.66B
-3.59%-10.04%+37.95%-5.52% 24.22B
Average -1.01%-3.13%+34.17%+151.04% 43B
Weighted average by Cap. -0.82%-3.01%+33.95%+135.00%

Financials

2026 *2027 *
Net sales 1.86B 1.7B 1.57B 1.42B 2.67B 174B 2.77B 18.95B 7.49B 93.87B 6.98B 6.84B 296B 2.99B 2.73B 2.52B 2.28B 4.29B 279B 4.45B 30.46B 12.04B 151B 11.22B 10.98B 476B
Net income -352M -321M -296M -268M -504M -32.85B -524M -3.58B -1.42B -17.73B -1.32B -1.29B -55.99B 164M 149M 138M 125M 235M 15.31B 244M 1.67B 659M 8.26B 615M 602M 26.09B
Net Debt -514M -469M -434M -391M -737M -48.07B -766M -5.24B -2.07B -25.95B -1.93B -1.89B -81.94B -949M -865M -800M -722M -1.36B -88.68B -1.41B -9.66B -3.82B -47.87B -3.56B -3.49B -151B
Projected Income Statement - Annual - Insmed Incorporated
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
18/11/26 $120.68 -0.97% 633,015
17/11/26 $121.86 -0.83% 2,398,022
16/11/26 $122.88 +1.42% 2,233,188
13/11/26 $121.16 +2.62% 1,543,624
12/11/26 $118.07 -2.22% 2,397,944
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Insmed Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
121.86USD
Average target price
194.18USD
Spread / Average Target
+59.35%
  1. Stock Market
  2. Stocks
  3. INSM Stock